Wikipedia
Niraparib
Niraparib (originally MK-4827) is an orally active small molecule PARP inhibitor being developed (by Tesaro) to treat ovarian cancer.
It is an inhibitor of PARP1 and PARP2.
Niraparib is due to be submitted for FDA approval (for maintenence therapy in ovarian cancer) later in 2016.
Chemically MK-4827 is CHNO (ignoring a possible tosylate group).